NHS Dudley Health Economy Medicines Formulary
Home > 10 Musculoskeletal and joint diseases > 10.1 Drugs used in rheumatic diseases and gout > 10.1.3 Drugs that suppress the rheumatic disease process > Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee - NICE TAG TA508

Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee - NICE TAG TA508

1.1 Autologous chondrocyte implantation (ACI) using chondrosphere is recommended as an option for treating symptomatic articular cartilage defects of the femoral condyle and patella of the knee (International Cartilage Repair Society grade III or IV) in adults, only if:

  • the person has not had previous surgery to repair articular cartilage defects

  • there is minimal osteoarthritic damage to the knee (as assessed by clinicians experienced in investigating knee cartilage damage using a validated measure for knee osteoarthritis) and

  • the defect is over 2 cm².

Why the committee made these recommendations

Current surgical treatments for symptomatic articular cartilage defects of the knee include microfracture, ACI and mosaicplasty.

Clinical trial results show that ACI using chondrosphere is as effective in the short term as microfracture, which is the most commonly used surgical option. But it is unclear how well chondrosphere works in the longer term compared with microfracture, because there are little data available beyond 2 years. Chondrosphere has greater benefit in articular cartilage defects larger than 2 cm².

The most plausible cost-effectiveness estimate for chondrosphere compared with microfracture is £4,360 per quality-adjusted life year (QALY) gained. However, this is likely to be an underestimate because it does not accurately consider the long-term effects of microfracture, which are uncertain. Defects larger than 2 cm² are often treated by best supportive care. The cost-effectiveness estimate for chondrosphere compared with best supportive care is likely to be lower than £20,000 per QALY gained, for defects larger than 2 cm².

https://www.nice.org.uk/guidance/ta508

Site by Devopa
© Copyright 2019 NHS. All rights reserved.